Inhaled Corticosteroids With/Without Long-Acting β-Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients
Inhaled Corticosteroids With/Without Long-Acting β-Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients
复制标题
吸入皮质类固醇联合/不联合长效β-激动剂可降低慢性阻塞性肺病患者再住院和死亡的风险
DOI：
10.1007/bf03256640
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
J. Vestbo
中科院分区：
文献类型：
--
作者：
J. Soriano;V. Kiri;N. Pride;J. Vestbo
摘要简介：在最近因疾病住院的慢性阻塞性肺疾病患者中，我们研究了吸入糖皮质激素而不加或加用长效β肾上腺素受体激动剂(β激动剂)是否减少了再住院和死亡率。
研究设计：英国全科医学研究数据库中的回顾性队列分析。
方法：我们比较了3636例接受吸入皮质类固醇或长效β激动剂处方的慢性阻塞性肺疾病患者和627例仅服用短效支气管扩张剂的慢性阻塞性肺疾病患者在首次住院后1年内因相关疾病或死亡而再次住院的情况。
结果：13.2%的慢性阻塞性肺疾病患者在一年内再次住院，14.0%的患者仅使用长效β激动剂，12.3%的患者仅使用吸入性皮质类固醇，10.4%的患者使用吸入性皮质类固醇和长效β激动剂。24.3%的慢性阻塞性肺疾病患者在一年内死亡，仅使用长效β激动剂的患者占17.3%，仅使用吸入性皮质类固醇的患者占17.1%，吸入型皮质类固醇和长效β激动剂的患者占10.5%。在多变量分析中，仅使用长效β激动剂(NS)的患者再住院或死亡的风险降低了10%，仅使用吸入性皮质类固醇(NS)的患者减少了16%，而联合使用吸入皮质类固醇和长效β激动剂(两者均为0.05)的患者再住院或死亡的风险降低了41%。
结论：吸入糖皮质激素与/或不与长效β激动剂一起使用与减少慢性阻塞性肺疾病患者的再住院或死亡有关。
AbstractIntroduction: In patients with COPD who have recently been hospitalized for their disease, we examined whether treatment with inhaled corticosteroids without or with long-acting β-adrenoceptor agonists (β-agonists) reduced rehospitalization and mortality.
Study design: Retrospective cohort analysis in the UK General Practice Research Database.
Methods: We compared rehospitalization for a COPD-related medical condition or death within 1 year after first hospitalization, in 3636 COPD patients receiving prescriptions for inhaled corticosteroids or long-acting β-agonists compared with 627 reference patients with COPD who were prescribed short-acting bronchodilators only.
Results: Rehospitalization within a year occurred in 13.2% of the reference COPD patients, 14.0% of users of long-acting β-agonists only, 12.3% of users of inhaled corticosteroids only, and 10.4% of users of inhaled corticosteroids and long-acting β-agonists. Death within a year occurred in 24.3% of the reference COPD patients, 17.3% of users of long-acting β-agonists only, 17.1% of users of inhaled corticosteroids only, and in 10.5% of users of inhaled corticosteroids and long-acting β-agonists. In multivariate analyses the risk of rehospitalization or death was reduced by 10% in users of long-acting β-agonists only (NS), by 16% in users of inhaled corticosteroids only, and by 41% in users of combined inhaled corticosteroids and long-acting β-agonists (both p < 0.05).
Conclusion: Use of inhaled corticosteroids with/without long-acting β-agonists was associated with a reduction of rehospitalization or death in COPD patients.
DOI：
10.1056/nejm200012283432601
发表时间：
2000-12
期刊：
The New England journal of medicine
影响因子：
--
作者：
R. Wise;J. Connett;G. Weinmann;P. Scanlon;M. Skeans
通讯作者：
R. Wise;J. Connett;G. Weinmann;P. Scanlon;M. Skeans